MediciNova, Inc. (MNOV)
$1.78
Rating:
Recommendation:
Buy
| Symbol | MNOV |
|---|---|
| Price | $1.78 |
| Beta | 0.909 |
| Volume Avg. | 0.10M |
| Market Cap | 87.302M |
| Shares () | - |
| 52 Week Range | 1.71-2.71 |
| 1y Target Est | - |
| DCF Unlevered | MNOV DCF -> | |
|---|---|---|
| DCF Levered | MNOV LDCF -> | |
| ROE | -14.14% | Sell |
| ROA | -13.90% | Sell |
| Operating Margin | - | |
| Debt / Equity | 1.03% | Neutral |
| P/E | -9.37 | Strong Sell |
| P/B | 1.35 | Strong Buy |
Latest MNOV news
About
Download (Excel)MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.